...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Was checking out SEDAR...

.....found that on Jan 27 Zenith issued a promissory note and 200,000 warrants with an exercise price of $.95CAN (exp Jan 27, 2027) and received $504,240.  This was with someone in Alberta, be interesting to know the details of the note and to who. 

Last week (Mar 23) 2 parties, one German one US, collectively purchased 300,000 units at a price of $1.26/unit.  Raised $378,000CAN.  Each unit has 1 share and 1 share purchase warrant exercisable for 1 year at $1.26.   Apparently Don is still selling Zenith at a premium to OTC (which is a joke) and a very deep discount (which is also a joke) to the Constellation benchmark.

Didn't see any 2022 RVX placements....

Share
New Message
Please login to post a reply